Saturday 17 October 2026
Export MGRX’s income statement to Excel — free account
Mangoceuticals, Inc.
MGRX Healthcare Health Information Services
Mangoceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $456,000.00, down 26.0% from fiscal 2024. In the quarter to June 2026, revenue fell 59.1%, EPS grew 84.2% and free cash flow grew 79.3%, each against the same quarter a year earlier.
0.30
0.02
−6.25%
Follow MGRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
54.07 | 16.34 | 14.31 | 20.63 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.33) | (6.91) | (4.52) | (24.97) | |
P/B ratio |
1.60 | 0.49 | 0.44 | 0.52 | |
Price to Tangible BV |
0.00 | 7.71 | 0.00 | 0.00 | |
EV/Sales |
53.04 | 13.08 | 13.89 | 19.91 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.19) | (1.02) | (1.18) | (1.61) | |
EV/FCF |
(4.24) | (1.03) | (1.19) | (1.64) | |
Quick Ratio |
0.60 | 1.67 | 0.24 | 0.16 | |
Current Ratio |
0.74 | 1.74 | 0.29 | 0.18 | |
Net Debt/EBITDA |
0.06 | (1.42) | 0.06 | 0.31 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.03 | 0.02 | 0.02 | |
Operating CF/Net income |
0.16 | 0.39 | 0.39 | 0.20 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(99.38) | 2.51 | (11.29) | (3.69) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
8,979.22% | 729.98% | 4,628.72% | 1,565.84% | |
Intangible Assets out of Total Assets |
0.96 | 0.88 | 0.96 | 0.96 | |
Share Based Compensation of Revenue |
6,583.25% | 63.56% | 867.60% | 116.28% | |
Graham Net Nets |
(0.01) | 0.09 | (0.13) | (0.22) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(162.56%) | (345.95%) | (413.89%) | (265.79%) | |
Free Cash Flow Yield |
(23.13%) | (77.62%) | (81.27%) | (58.81%) | |
Revenue per Share |
0.01 | 0.01 | 0.00 | 0.00 | |
Operating CF per Share |
(0.11) | (0.11) | (0.08) | (0.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.11) | (0.11) | (0.08) | (0.02) | |
Cash per Share |
0.04 | 0.15 | 0.01 | 0.01 | |
Shareholders Equity per Share |
1.36 | 1.51 | 0.82 | 0.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.36 | 1.51 | 0.82 | 0.73 | |
Free Cash Flow |
(1.24) | (1.08) | (1.31) | (0.26) | |
Working Capital |
(0.21) | 0.66 | (0.53) | (1.15) | |
Net Current Asset Value |
(0.21) | 0.66 | (0.76) | (1.40) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.64 | 0.63 | 0.85 | 0.85 | |
Average Assets |
15.66 | 15.73 | 18.10 | 17.51 | |
Average Common Equity |
14.56 | 14.57 | 16.86 | 15.88 |
Columns are period end dates · fundamentals updated 2 Oct 2026